Clinical trials · Wisconsin
Chronic Myeloid Leukemia clinical trials in Wisconsin
We’re tracking 18 recruiting chronic myeloid leukemia studies with a site in Wisconsin — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Wisconsin
- NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Antigo, WisconsinAges 40–75 - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Appleton, WisconsinAges 18–59 - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Milwaukee, WisconsinAges 18 years+ - NCT04835584RecruitingPhase 1/Phase 2
Testing KRT-232 with a TKI for CML that didn’t respond
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
Milwaukee, WisconsinAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Milwaukee, WisconsinAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Milwaukee, WisconsinAges 18 years+ - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Milwaukee, WisconsinAges 18 years+ - NCT06222580RecruitingPhase 1
Combination of two targeted drugs for resistant FLT3-mutated AML
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Madison, WisconsinAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Madison, WisconsinAges 18 years+ - NCT05317403RecruitingPhase 1
Venetoclax plus chemo to change cancer cell behavior
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
Milwaukee, WisconsinAges 1–25 - NCT06317649RecruitingPhase 2
Venetoclax and HMA for older adults with FLT3-mutated AML
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
Appleton, WisconsinAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Ashland, WisconsinAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
La Crosse, WisconsinAges 18–59 - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Eau Claire, WisconsinAges 18 years+ - NCT04771130RecruitingPhase 1/Phase 2
Study of BGB-11417 for blood cancers
This early-phase study tests BGB-11417 in people with certain bone-marrow (blood) cancers such as AML, MDS, or MDS/MPN. The goal is to find out how the medicine works and whether it can control the cancer.
Milwaukee, WisconsinAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Appleton, WisconsinAges 18–59 - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Madison, WisconsinAges 18 years+
Chronic Myeloid Leukemia trials by city in Wisconsin
Where these studies are running in Wisconsin
Institutions with a site for the recruiting chronic myeloid leukemia studies listed above.
- Medical College of Wisconsin · 7 studies
- Gundersen Lutheran Medical Center · 6 studies
- Duluth Clinic Ashland · 5 studies
- Saint Vincent Hospital Cancer Center · 5 studies
- Froedtert & the Medical College of Wisconsin · 4 studies
- Marshfield Medical Center - Weston · 4 studies
- Marshfield Medical Center-River Region at Stevens Point · 4 studies
- ThedaCare Regional Cancer Center · 4 studies
What taking part in a chronic myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Chronic Myeloid Leukemia trials in other states
Common questions
- Are there chronic myeloid leukemia clinical trials in Wisconsin?
- Yes. We're currently tracking 18 recruiting chronic myeloid leukemia studies with a site in Wisconsin, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic myeloid leukemia study in Wisconsin?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Wisconsin to take part?
- Not necessarily. These studies have a site in Wisconsin, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic myeloid leukemia studies open in Wisconsin regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.